PMN
ProMIS Neurosciences·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
PMN Profile
Promis Neurosciences Inc.
A company that developing therapeutics for alzheimer's, amyotrophic lateral sclerosis, and parkinson's disease
Biological Technology
01/23/2004
07/08/2022
NASDAQ Stock Exchange
7
12-31
Common stock
Suite 200, 1920 Yonge Street , Toronto, Ontario , M4S 3E2
--
ProMIS Neurosciences Inc., incorporated on January 23, 2004 under the Canadian Business Corporations Act, is located at 1920 Yonge Street, Toronto, Ontario. The company is applying its patented technology platform to build a combination of antibody therapies, therapeutic vaccines and other antibody-based therapies in neurodegenerative diseases and other misfolded protein diseases, including Alzheimer's disease multi-system atrophy and amyotrophic lateral sclerosis. The company also plans to study other synuclein diseases, including Parkinson's disease and Lewy body dementia, frontotemporal lobe degeneration, progressive supranuclear palsy, corticobasal ganglia degeneration and schizophrenia. These diseases have a common biological cause — misfolded proteins that otherwise function normally, become toxic and kill neurons, leading to disease. ProMIS 'technology platform is an example of progress in drug discovery through computing power, computer discovery and artificial intelligence.
